COVID-19, immunocompromised host, dual anti-SARS-CoV-2 therapies, combination therapy, prolonged viral shedding, individualized therapeutic approaches
COVID-19, SARS-CoV-2, chemokines, t cells, mRNA vaccination, B cells, monocytes, NK cells
giant cell arteritis, monitoring, imaging, ultrasound, follow-up
immune check point inhibition (ICI), head and neck sqamous cell carcinoma (HNSCC), CD103+ tissue-resident T cells